Hosted on MSN8m
Hims & Hers cut to underperform by BoA over Amazon competition
BofA has lowered its rating of Hims & Hers (NYSE:HIMS) to underperform from buy, citing Amazon’s (AMZN) push into the hair ...
Swissinfo11m
Stocks Lose Steam as Rally Goes Too Far, Too Fast: Markets Wrap
(Bloomberg) — Stocks lost traction following a furious post-election rally that spurred calls for a breather amid signs of buyer fatigue. Equities fell from near all-time highs, with the S&P 500 ...
New FDA rules for TV drug ads: Simpler language and no distractions
The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...
Hosted on MSN20m
Amazon launches fixed pricing for treatment of conditions such as hair loss. Hims & Hers stock drops 15%
The move places the company in competition with other direct-to-consumer marketplaces including Hims & Hers Health and Ro.
Amazon launches lifestyle drug service as challenge to Hims & Hers
The announcement is Amazon’s most recent move into the pharmacy space Amazon Amazon continued its move into the pharmacy ...
Hims & Hers falls -17.7%
Hims & Hers (HIMS) is down -17.7%, or -$4.88 to $22.72. Published first on TheFly – the ultimate source for real-time, ...
Amazon service a threat to Hims & Hers’ core offering, says Citi
After Amazon (AMZN) announced its launch of its Amazon One Medical Pay-per-visit telehealth service, which is “very similar” to ...
wqad57m
FDA puts new restrictions on TV ads for drugs
FDA’s requirement for truthful, balanced risk and benefit information applies to drugmakers, leaving a loophole for both ...